OS Therapies

OSTX · NYSE American

$1.26−$0.01 (−0.79%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $1.27

OSTX analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $8.67 (+588.1% upside)

Low: $6.06
Now: $1.26
High: $13.65

Upgrades and downgrades

The latest rating actions, newest first

OSTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Roth Capital	Jul 9, 2026	Initiates	Buy	$7.00	17%
Lake Street	May 19, 2026	Maintains	Buy	$14.00 → $13.00	27%
D. Boral Capital	Apr 30, 2026	Maintains	Buy	$20.00	29%
D. Boral Capital	Apr 8, 2026	Maintains	Buy	$20.00	29%
D. Boral Capital	Mar 27, 2026	Maintains	Buy	$20.00	29%
D. Boral Capital	Mar 9, 2026	Maintains	Buy	$20.00	29%
D. Boral Capital	Feb 5, 2026	Maintains	Buy	$20.00	29%
D. Boral Capital	Jan 5, 2026	Maintains	Buy	$20.00	29%
D. Boral Capital	Dec 15, 2025	Maintains	Buy	$20.00	29%
D. Boral Capital	Dec 9, 2025	Maintains	Buy	$20.00	29%

The case for and against

Updated Sep 30, 2026

Bull case

OS Therapies is a promising company with potential in their pipeline of product candidates addressing solid cancers, particularly osteosarcoma. While they have a heavy cost structure and financial concerns, their positive update and potential EMA CMA decision in 2026 could lead to European peak sales potential above $300M and a potential PRV eligibility. However, the success of their accelerated approval path depends on their ability to execute against regulatory milestones and convert Phase 2b and biomarker data. There are also potential risks, such as clinical/regulatory risk, partnership and financial risk, commercial risk, legal and intellectual property risk, and market share risk, to consider.

Bear case

OS Therapies is heavily reliant on OST-HER2, a yet-to-be approved immunotherapy drug with uncertain efficacy and safety data, as its main source of potential revenue in the near future. Additionally, the company's financials show a lack of cash flow and significant debt, which may make it difficult for them to continue developing and commercializing their drug candidates without additional funding. With these risks and uncertainties in mind, a negative outlook on OS Therapies's stock seems reasonable in the current stage of the company's development.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.